These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19371962)

  • 1. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis.
    Na II; Byun BH; Kim KM; Cheon GJ; Choe du H; Koh JS; Lee DY; Ryoo BY; Baek H; Lim SM; Yang SH; Kim CH; Lee JC
    Lung Cancer; 2010 Jan; 67(1):76-80. PubMed ID: 19371962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: a retrospective analysis of 206 patients.
    Lee SM; Bae SK; Jung SJ; Kim CK
    Clin Nucl Med; 2015 Dec; 40(12):950-8. PubMed ID: 26359571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.
    Mak RH; Digumarthy SR; Muzikansky A; Engelman JA; Shepard JA; Choi NC; Sequist LV
    Oncologist; 2011; 16(3):319-26. PubMed ID: 21339258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-fluoro-2-deoxy-glucose uptake predicts clinical outcome in patients with gefitinib-treated non-small cell lung cancer.
    Na II; Byun BH; Kang HJ; Cheon GJ; Koh JS; Kim CH; Choe DH; Ryoo BY; Lee JC; Lim SM; Yang SH
    Clin Cancer Res; 2008 Apr; 14(7):2036-41. PubMed ID: 18381942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of Glut-1 glucose transporter expression with.
    Higashi K; Ueda Y; Sakurai A; Wang XM; Xu L; Murakami M; Seki H; Oguchi M; Taki S; Nambu Y; Tonami H; Katsuda S; Yamamoto I
    Eur J Nucl Med; 2000 Dec; 27(12):1778-85. PubMed ID: 11189940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of
    Lv Z; Fan J; Xu J; Wu F; Huang Q; Guo M; Liao T; Liu S; Lan X; Liao S; Geng W; Jin Y
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):735-750. PubMed ID: 29164298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
    Higashi K; Ueda Y; Arisaka Y; Sakuma T; Nambu Y; Oguchi M; Seki H; Taki S; Tonami H; Yamamoto I
    J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma.
    Huang CT; Yen RF; Cheng MF; Hsu YC; Wei PF; Tsai YJ; Tsai MF; Shih JY; Yang CH; Yang PC
    Med Oncol; 2010 Mar; 27(1):9-15. PubMed ID: 19130320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of multiple metabolic and heterogeneity parameters of
    Shi A; Wang J; Wang Y; Guo G; Fan C; Liu J
    Ann Nucl Med; 2022 Apr; 36(4):393-400. PubMed ID: 35084711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy.
    Lee KH; Lee SH; Kim DW; Kang WJ; Chung JK; Im SA; Kim TY; Kim YW; Bang YJ; Heo DS
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4232-6. PubMed ID: 16857796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of 18F-FDG uptake on positron emission tomography in patients with pathologic stage I non-small cell lung cancer.
    Um SW; Kim H; Koh WJ; Suh GY; Chung MP; Kwon OJ; Choi JY; Han J; Lee KS; Kim J
    J Thorac Oncol; 2009 Nov; 4(11):1331-6. PubMed ID: 19701106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer.
    Liu A; Han A; Zhu H; Ma L; Huang Y; Li M; Jin F; Yang Q; Yu J
    Oncotarget; 2017 May; 8(20):33736-33744. PubMed ID: 28422710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological correlates of FDG uptake in non-small cell lung cancer.
    de Geus-Oei LF; van Krieken JH; Aliredjo RP; Krabbe PF; Frielink C; Verhagen AF; Boerman OC; Oyen WJ
    Lung Cancer; 2007 Jan; 55(1):79-87. PubMed ID: 17046099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
    van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
    Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer.
    Cho A; Hur J; Moon YW; Hong SR; Suh YJ; Kim YJ; Im DJ; Hong YJ; Lee HJ; Kim YJ; Shim HS; Lee JS; Kim JH; Choi BW
    BMC Cancer; 2016 Mar; 16():224. PubMed ID: 26979333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of 18F-FDG uptake on PET in non-small cell lung cancer patients with postoperative recurrence following platinum-based chemotherapy.
    Kaira K; Yamamoto N; Kenmotsu H; Murakami H; Ono A; Naito T; Endo M; Takahashi T
    Respir Investig; 2014 Mar; 52(2):121-8. PubMed ID: 24636268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense?
    Hellwig D; Graeter TP; Ukena D; Groeschel A; Sybrecht GW; Schaefers HJ; Kirsch CM
    J Nucl Med; 2007 Nov; 48(11):1761-6. PubMed ID: 17942814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis.
    Chen L; Zhou Y; Tang X; Yang C; Tian Y; Xie R; Chen T; Yang J; Jing M; Chen F; Wang C; Sun H; Huang Y
    Int J Oncol; 2019 Jan; 54(1):370-380. PubMed ID: 30431083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiologic Characteristics of Surgically Resected Non-Small Cell Lung Cancer With ALK Rearrangement or EGFR Mutations.
    Kim TJ; Lee CT; Jheon SH; Park JS; Chung JH
    Ann Thorac Surg; 2016 Feb; 101(2):473-80. PubMed ID: 26454747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG uptake as a biologic factor predicting outcome in patients with resected non-small-cell lung cancer.
    Zhang ZJ; Chen JH; Meng L; Du JJ; Zhang L; Liu Y; Dai HH
    Chin Med J (Engl); 2007 Jan; 120(2):125-31. PubMed ID: 17335654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.